By SPC News Staff
Researchers from Harvard Medical School found non-ictal cephalic allodynia, established by a quick, inexpensive and noninvasive proprietary test, is an 86% accurate pretreatment predictor of anti-calcitonin gene–related peptide (CGRP) therapy response (Cephalalgia 2023 Feb 14.https://doi.org/10.1177/033310242211478).
Only about 50% of migraine patients respond to anti-CGRP therapy, but it was impossible to know which 50% would respond to treatment before prescribing